FibroBiologics, Inc.
NASDAQFibroBiologics heads into its May 8 earnings report with a fresh analyst downgrade sharpening the bear case just days before the release. On Monday, Maxim Group cut the stock from Buy to Hold — a timing that is hard to ignore. The move follows HC Wainwright's April 16 target raise to $8 from $4, which maintains a Buy rating. That split verdict captures the core tension: one firm…
FBLG short interest
Full pulse commentary is for ORTEX subscribers. The live data picture for FBLG below stays open — short interest, options flow, signals, and historical context.
Sign up free to read pulse →Short interest % of float, cost to borrow, utilization, and put/call ratio for FBLG are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Snapshot as of 7 May 2026
FibroBiologics heads into its May 8 earnings report with a fresh analyst downgrade sharpening the bear case just days before the release. On Monday, Maxim Group cut the stock from Buy to Hold — a timing that is hard to…
FibroBiologics arrives at its May 8 earnings date carrying two conflicting signals: a stock up 11% on the week and a $6.15 million equity offering announced May 1 that immediately frames how that rally will be…
FBLG heads into its May 1 earnings release as one of the most internally-owned small biotech stories in the market — with nearly every C-suite member having bought shares in the open market just weeks ago. The insider…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for FBLG — free to start on ORTEX.
Sign up for free →Open FBLG on ORTEX